Etiopathogenesis of medication-related osteonecrosis of the jaws: a review
This study compiles the main hypotheses involved in the etiopathogenesis of medication-related osteonecrosis of the jaw (MRONJ). A narrative review of the literature was performed. The etiopathogenesis of MRONJ is multifactorial and not fully understood. The main hypothesis considers the disturbance of bone turnover caused by anti-resorptive drugs. Bisphosphonates and denosumab inhibit osteoclast activity through different action mechanisms, accumulating bone microfracture. Other hypotheses also consider oral infection and inflammation, the antiangiogenic effect and soft tissue toxicity of bisphosphonates, and the inhibiti...
Source: Journal of Molecular Medicine - February 2, 2024 Category: Molecular Biology Source Type: research
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors
ConclusionsTBS variation predicts fracture risk in AIs treated women. Denosumab is effective to induce early increase of TBS and reduction in risk of VFs. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - February 1, 2024 Category: Endocrinology Source Type: research
Cancers, Vol. 16, Pages 627: Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer
Shi
Tie Zhou
In the absence of early detection and initial treatment, prostate cancer often progresses to an advanced stage, frequently spreading to the bones and significantly impacting patients’ well-being and healthcare resources. Therefore, managing patients with prostate cancer that has spread to the bones often involves using bone-targeted medications like bisphosphonates and denosumab to enhance bone structure and minimize skeletal complications. Additionally, researchers are studying the tumor microenvironment and biomarkers to understand the mechanisms and potential treatment targets for bone ...
Source: Cancers - January 31, 2024 Category: Cancer & Oncology Authors: Wenhao Zhou Wei Zhang Shi Yan Kaixuan Zhang Han Wu Hongyu Chen Minfeng Shi Tie Zhou Tags: Review Source Type: research
To the Bone: Experts Discuss Developments in Osteoporosis Care
During ACR Convergence 2023, experts discussed developments in the treatment and diagnosis of osteoporosis, addressing risks of treatment discontinuation, the use of bone turnover markers in patient assessment and vitamin D. (Source: The Rheumatologist)
Source: The Rheumatologist - January 29, 2024 Category: Rheumatology Authors: Thomas R. Collins Tags: ACR Convergence Conditions Osteoarthritis and Bone Disorders ACR Convergence 2023 denosumab Osteoporosis Vitamin D Source Type: research
